Ellen R A Van Gulck - Infectious Diseases

Author Information

Ellen R. Van Gulck is affiliated with Janssen Infectious Diseases and Vaccines, part of Janssen Research and Development, which is a division of Janssen Pharmaceutica NV, located in Beerse, Belgium. Her research work primarily focuses on infectious diseases, with a particular interest in vaccine development and immune response modulation.

Research Contributions

Ellen R. Van Gulck has made significant contributions to the field of infectious diseases through her research on vaccines and immunotherapies. Her work spans various topics, including the development of DNA vaccines against Hepatitis B, the creation of stable formulations for respiratory syncytial virus proteins, and the exploration of immune responses in HIV-1 infected patients. Her research often involves innovative approaches to vaccine delivery systems and aims to enhance antigen-specific immune responses.

Aliases

Ellen R. Van Gulck is also known by other names in academic publications, including E. Van Gulck, Ellen Van Gulck, E. van Gulck, and Ellen R A Van Gulck.

Publication and Citation Metrics

Metric	Value
Number of Papers	28
H-index	14
Total Citations	822

Publications:

A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates

DOI: 10.3390/vaccines9090969

Year: 2021

Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study

DOI: 10.3390/pharmaceutics11100510

Year: 2019

Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice

DOI: 10.1371/journal.pone.0202961

Year: 2018

Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines.

DOI: 10.1038/mt.2012.202

Year: 2013

An antibody response to human polyomavirus 15-mer peptides is highly abundant in healthy human subjects

DOI: 10.1186/1743-422X-10-192

Year: 2013

Targeting of Human Antigen-Presenting Cell Subsets

DOI: 10.1128/JVI.01498-13

Year: 2013

Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses.

DOI: 10.2217/nnm.12.97

Year: 2013

Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery.

DOI: 10.1016/j.biomaterials.2011.10.004

Year: 2012

Immune and Viral Correlates of “Secondary Viral Control” after Treatment Interruption in Chronically HIV-1 Infected Patients

DOI: 10.1371/journal.pone.0037792

Year: 2012

Can immunotherapy be useful as a “functional cure” for infection with Human Immunodeficiency Virus-1?

DOI: 10.1186/1742-4690-9-72

Year: 2012

What are the Treatment Options?

How are DAAs used in combination therapies?

Why is Fever Management Important in Infectious Diseases?

What Are the Key Strategies in Preventing Infectious Diseases?

What is Food and Water Contamination?

What is an Infectious Disease Surveillance System?

What are Antimicrobial Therapies?

How Does the CDC Engage with the Public?

How Do We Diagnose Infections?

What Are the Challenges in Controlling Aedes Aegypti?

Partnered Content Networks

Relevant Topics